URGN vs. NKTR

Last updated Apr 2, 2026

Compare and contrast key facts about UroGen Pharma Ltd. (URGN) and Nektar Therapeutics (NKTR).

Performance

URGN vs. NKTR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in UroGen Pharma Ltd. (URGN) and Nektar Therapeutics (NKTR). The values are adjusted to include any dividend payments, if applicable.

URGN vs. NKTR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
URGN UroGen Pharma Ltd.	-19.13%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%
NKTR Nektar Therapeutics	79.07%	203.08%	64.60%	-75.00%	-83.27%	-20.53%	-21.26%	-34.32%	-44.96%	221.42%

Fundamentals

Market Cap URGN : $932.42M NKTR : $1.54B
EPS URGN : -$3.18 NKTR : -$10.15
PS Ratio URGN : 8.34 NKTR : 22.15
Total Revenue (TTM) URGN : $109.79M NKTR : $55.23M
Gross Profit (TTM) URGN : $97.34M NKTR : $55.04M
EBITDA (TTM) URGN : -$127.69M NKTR : -$122.97M

Returns By Period

In the year-to-date period, URGN achieves a -19.13% return, which is significantly lower than NKTR's 79.07% return.

URGN

• 1D: 5.34%
• 1M: -0.42%
• YTD: -19.13%
• 6M: 6.31%
• 1Y: 78.17%
• 3Y*: 27.03%
• 5Y*: -0.71%
• 10Y*: —

NKTR

• 1D: 5.23%
• 1M: 10.75%
• YTD: 79.07%
• 6M: 28.65%
• 1Y: 691.99%
• 3Y*: 92.93%
• 5Y*: -24.37%
• 10Y*: -9.98%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

URGN vs. NKTR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

URGN

URGN Risk / Return Rank: 69
URGN Sharpe Ratio Rank: 65
URGN Sortino Ratio Rank: 73
URGN Omega Ratio Rank: 76
URGN Calmar Ratio Rank: 64
URGN Martin Ratio Rank: 66

NKTR

NKTR Risk / Return Rank: 99
NKTR Sharpe Ratio Rank: 98
NKTR Sortino Ratio Rank: 99
NKTR Omega Ratio Rank: 98
NKTR Calmar Ratio Rank: 99
NKTR Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

URGN vs. NKTR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Nektar Therapeutics (NKTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	URGN	NKTR	Difference
Sharpe ratio Return per unit of total volatility	0.69	3.69	-3.00
Sortino ratio Return per unit of downside risk	1.78	5.91	-4.14
Omega ratio Gain probability vs. loss probability	1.27	1.67	-0.40
Calmar ratio Return relative to maximum drawdown	1.08	13.80	-12.73
Martin ratio Return relative to average drawdown	3.00	33.65	-30.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

URGN vs. NKTR - Sharpe Ratio Comparison

The current URGN Sharpe Ratio is 0.69, which is lower than the NKTR Sharpe Ratio of 3.69. The chart below compares the historical Sharpe Ratios of URGN and NKTR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	URGN	NKTR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.69	3.69	-3.00
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.01	-0.20	+0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.10	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.04	0.01	+0.03

Correlation

The correlation between URGN and NKTR is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

URGN vs. NKTR - Dividend Comparison

Neither URGN nor NKTR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

URGN vs. NKTR - Drawdown Comparison

The maximum URGN drawdown since its inception was -93.98%, smaller than the maximum NKTR drawdown of -99.61%. Use the drawdown chart below to compare losses from any high point for URGN and NKTR.

Drawdown Indicators

	URGN	NKTR	Difference
Max Drawdown Largest peak-to-trough decline	-93.98%	-99.61%	+5.63%
Max Drawdown (1Y) Largest decline over 1 year	-66.24%	-46.54%	-19.70%
Max Drawdown (5Y) Largest decline over 5 years	-82.64%	-97.93%	+15.29%
Max Drawdown (10Y) Largest decline over 10 years	—	-99.61%	—
Current Drawdown Current decline from peak	-71.01%	-95.35%	+24.34%
Average Drawdown Average peak-to-trough decline	-61.55%	-68.17%	+6.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.79%	19.09%	+4.70%

Volatility

URGN vs. NKTR - Volatility Comparison

The current volatility for UroGen Pharma Ltd. (URGN) is 15.35%, while Nektar Therapeutics (NKTR) has a volatility of 17.64%. This indicates that URGN experiences smaller price fluctuations and is considered to be less risky than NKTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	URGN	NKTR	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.35%	17.64%	-2.29%
Volatility (6M) Calculated over the trailing 6-month period	49.37%	65.68%	-16.31%
Volatility (1Y) Calculated over the trailing 1-year period	113.74%	189.39%	-75.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.48%	121.48%	-30.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.73%	96.96%	-17.23%

Financials